Engelsk

Subject - Sample Mapping (including mapping to Coriell IDs)

19 Formulär  
  1. StudyEvent: NEI Age-Related Eye Disease Study (AREDS)
    1. Eligibility Criteria
    2. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    3. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    9. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    10. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    15. Subject - Consent Information
    16. Subject - Sample Mapping (including mapping to Coriell IDs)
    17. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
pht002478
Beskrivning

pht002478

De-identified subject ID
Beskrivning

ID2

Datatyp

text

Alias
UMLS CUI [1,1]
C2348585
De-identified sample ID
Beskrivning

specnum

Datatyp

text

Alias
UMLS CUI [1,1]
C1299222
Source/origin of sample
Beskrivning

SAMP_SOURCE

Datatyp

text

Alias
UMLS CUI [1,1]
C0449416
UMLS CUI [1,2]
C0200345
Sample ID used at the source
Beskrivning

SOURCE_SAMPID

Datatyp

text

Alias
UMLS CUI [1,1]
C1299222
UMLS CUI [1,2]
C0449416
DbGaP top-level study or substudy accession: phs000001.v3.p1 AREDS and phs000429.v1.p1 CIDR Refractive Error
Beskrivning

STUDY

Datatyp

text

Alias
UMLS CUI [1,1]
C0034951
Sample use (When left blank no genotype data available through dbGaP but samples are available through Coriell.)
Beskrivning

SAMPLE_USE

Datatyp

text

Alias
UMLS CUI [1,1]
C0200345
UMLS CUI [1,2]
C0457083
Tillbaka till toppen

Similar models

Subject - Sample Mapping (including mapping to Coriell IDs)

19 Formulär
  1. StudyEvent: NEI Age-Related Eye Disease Study (AREDS)
    1. Eligibility Criteria
    2. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    3. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    9. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    10. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    15. Subject - Consent Information
    16. Subject - Sample Mapping (including mapping to Coriell IDs)
    17. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
pht002478
ID2
Item
De-identified subject ID
text
C2348585 (UMLS CUI [1,1])
specnum
Item
De-identified sample ID
text
C1299222 (UMLS CUI [1,1])
SAMP_SOURCE
Item
Source/origin of sample
text
C0449416 (UMLS CUI [1,1])
C0200345 (UMLS CUI [1,2])
SOURCE_SAMPID
Item
Sample ID used at the source
text
C1299222 (UMLS CUI [1,1])
C0449416 (UMLS CUI [1,2])
STUDY
Item
DbGaP top-level study or substudy accession: phs000001.v3.p1 AREDS and phs000429.v1.p1 CIDR Refractive Error
text
C0034951 (UMLS CUI [1,1])
Item
Sample use (When left blank no genotype data available through dbGaP but samples are available through Coriell.)
text
C0200345 (UMLS CUI [1,1])
C0457083 (UMLS CUI [1,2])
SAMPLE_USE
Code List
Sample use (When left blank no genotype data available through dbGaP but samples are available through Coriell.)
CL Item
SNP genotypes obtained using standard or custom microarrays (SNP_Array)
Tillbaka till toppen